The Celsius Fork: Better-For-You or Better-For-Profit?

Celsius spent two years convincing investors that Alani Nu's growth story was a wellness play. The marketing that made those numbers work also got a 17-year-old killed. Now the same investors who bought the wellness narrative are sitting on a securities fraud class action claiming Celsius hid the health risks all along.

Let's trace the actual money and the actual risk.

The Acquisition That Changed the Story

Celsius Holdings bought Alani Nu on April 1, 2025, for a net $1.65 billion — cash and stock. At the time, Celsius's market cap was roughly $6 billion. They paid less than 3 times Alani Nu's 2024 revenue of $595 million, calling it "accretive to cash EPS in the first full year of ownership."

The pitch was clean: Alani Nu was a female-focused, Gen Z, wellness-adjacent brand growing at 78% year-over-year. It would complement Celsius's core energy drink and create what the company called "a leading better-for-you functional lifestyle platform."

The phrase matters: better-for-you. It isn't marketing decoration — it was the valuation justification. A better-for-you brand trades at higher multiples than a standard energy drink because investors believe it carries lower regulatory risk, broader consumer appeal, and more durable growth. Celsius priced the acquisition as though Alani Nu earned that classification.

But each 12-ounce Alani Nu can contains 200 milligrams of caffeine. That's double what the American Academy of Pediatrics recommends as a daily maximum for teenagers aged 12 to 17. Canada had already recalled Alani Nu drinks in August 2023 because that same 200-milligram dose exceeded its legal cap of 180 milligrams per serving.

The can warns against consumption by children. It does not warn teenagers with equivalent force.

The Numbers That Made the Story Work

Celsius reported Q1 2026 revenue of $782.6 million — a 138% year-over-year surge. Alani Nu generated $368.1 million in that quarter alone, roughly 47% of total revenue in its first full quarter under Celsius ownership.

But the margin story told a different tale. Gross margins fell from 52.3% in Q1 2025 to 48.3% in Q1 2026. Alani Nu and the smaller Rockstar Energy acquisition came with structurally lower cost profiles. Celsius management guided for margins to "sidestep" in Q2 and said low-50s margins were a 2027 target.

By Q2 2026, the picture sharpened. Total revenue of $817.9 million missed analyst expectations by roughly $55 million. Net income fell 45% year-over-year, from $99.9 million to $55.3 million. Gross margins sat at 48.1%, down 340 basis points from a year earlier.

And here's the number that matters most for the growth thesis: brand Celsius revenue declined 11.7% year-over-year in Q2 2026. Alani Nu contributed roughly $364.4 million — about 45% of total revenue. Rockstar Energy, the other acquisition, also declined 13%.

The company that traded as a growth monopoly is now dependent on an acquired brand for growth, and that acquired brand carries both the lowest margins in the portfolio and the heaviest liability cloud.

The Fork

In October 2025, 17-year-old Larissa Rodriguez died in Weslaco, Texas. She was a high school student and cheerleader with no pre-existing heart conditions. The Hidalgo County medical examiner determined the cause of death was an enlarged heart due to stress and large amounts of caffeine. Toxicology tests were negative for drugs and alcohol. The only substance in her system was caffeine.

Her family says she drank at least one Alani Nu daily, sometimes more — during morning routines, school, and sports. They filed a wrongful death lawsuit in April 2026 against Alani Nu distributors, seeking more than $1 million in damages, alleging inadequate warnings about cardiac risks. Celsius wasn't named as a defendant initially, but the family's attorney said more defendants would likely be added as discovery continued. A motion to dismiss was denied in July 2026.

Celsius responded that its policy is "not to market or sample to anyone under 18." They noted the can discloses 200mg of caffeine.

But the complaint in the securities fraud class action filed by Pomerantz LLP on September 2, 2026, makes a sharper allegation: that Celsius's marketing practices — colorful packaging, influencer recruiting on college campuses, an "Alani Ambassadors" social media program that acknowledges up to 25% of some social media audiences are under 18 — deliberately targeted the exact demographic most vulnerable to cardiac risk. The complaint class period runs from February 21, 2025, to June 3, 2026.

On June 4, 2026, Texas Attorney General Ken Paxton announced his office was investigating whether Celsius "knowingly marketed" high-caffeine energy drinks to children and teens, citing "colorful packaging, playful design elements, and youth-oriented branding strategies." Celsius shares fell 7.5% that day to $27.75.

The fork was this: Celsius could either maintain the "better-for-you" narrative that justified the acquisition premium — and the stock price that came with it — or acknowledge that the growth machine depended on a brand whose safety profile looked significantly different when teenagers were the primary consumer. They chose to maintain the narrative. The invoice arrived anyway.

The Two Claimants

Here are the competing interests, priced out.

Investors who bought the growth story. The class action covers purchases from February 21, 2025 through June 3, 2026. During that window, Celsius stock traded between roughly $28 and $67. The company's market cap peaked near $20 billion in 2024 before collapsing to approximately $3.1 billion at the current price of $26.63. That's a decline of more than 70% from the high. The stock is down roughly 49.5% over the past three years in total return terms.

These investors bought into a story where Alani Nu was durable growth at attractive margins, backed by a "better-for-you" positioning that insulated the brand from regulatory headwinds. If the securities complaint has merit, the foundation of that story — the safety and marketing compliance of the acquired brand — was materially misrepresented.

The growth strategy itself. Celsius needed Alani Nu because its own brand couldn't sustain the growth trajectory that justified its valuation. Even before the acquisition, the company was transitioning from a disruptor to a defender. The core Celsius brand grew just 6% in Q1 2026 — and that was after deliberate SKU rationalization that cleared lower-velocity items from shelves. By Q2, it was declining 11.7%.

The acquisition was supposed to fix that. Instead, it transferred the dependency. Alani Nu now represents roughly 45% of revenue, carries the lowest margin profile, and is the subject of a state investigation and a pending wrongful death lawsuit. The growth isn't gone — Alani Nu retail sales grew 55.7% in Q2 — but it may be growth that the brand can no longer sustain once its marketing model comes under regulatory fire.

The Unpaid Invoice

Celsius's balance sheet isn't breaking. The company has $631 million in cash and short-term investments against $675 million in total debt. Shareholder equity sits at roughly $3 billion. The leverage from the Alani Nu acquisition is manageable.

The real cost isn't on the balance sheet. It's in the gap between what investors paid and what the business now looks like.

Celsius currently trades at approximately 127.8 times trailing earnings. The beverage industry average is 17.5x. The peer group average is 36.6x. An implied fair P/E of 31.2x suggests the stock still has little room for further disappointment on growth or profitability. At that multiple, investors are pricing in a recovery that requires both the core brand to stabilize and Alani Nu to grow without the regulatory and reputational drag that now surrounds it.

That's a tall order. The company said its portfolio contributed 30% of the zero-sugar U.S. energy category's $640 million growth in Q2 2026, and the combined portfolio holds roughly 20.1% market share. Those are real numbers. But they're numbers built on a marketing machine that Texas's Attorney General is now probing and a wrongful death family is arguing killed their daughter.

The securities class action alleges that Celsius failed to disclose this risk during a period when it was simultaneously telling investors the acquisition was accretive, telling the public the products were safe and healthy, and telling the market that "better-for-you" was a sustainable competitive advantage.

The stock has already fallen 70% from its peak. Today it's down another 3.7% to $26.63. But the class action doesn't measure whether the stock fell enough. It measures whether the fall was caused by information the company should have disclosed and didn't.

For investors watching from the sidelines, the question isn't whether Celsius deserves sympathy. It's whether a company can sustain its valuation when the growth story and the liability story are the same story — and the market hasn't decided which one runs longer. The lawsuit gives shareholders a legal mechanism to address the first half. No one has priced in the cost of the second.